N. Bodick

发表

Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.

A L Goldberger, A. Goldberger, L. Lipsitz, 1997, Hypertension.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

W W Offen, A. Levey, S. Gauthier, 1997, Archives of neurology.

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

F. Bymaster, L. Farde, P. Suzdak, 1997 .

Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis.

A. Bendele, N. Bodick, A. Kumar, 2015, Osteoarthritis and cartilage.

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.

P. Renshaw, W. Offen, A. Satlin, 1997, The American journal of psychiatry.

Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study

S. Russell, P. Conaghan, A. Kivitz, 2018, Rheumatology.

Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis

A. Kivitz, N. Bodick, J. R. Johnson, 2017 .

Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

R. Mohs, S. Gauthier, J. Orgogozo, 1997, Alzheimer disease and associated disorders.

Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs

V. Strand, R. Boyce, N. Bodick, 2018, Rheumatology and Therapy.

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain

D. Jevsevar, D. Hunter, F. Berenbaum, 2018, The Journal of bone and joint surgery. American volume.

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

W W Offen, S. Paul, S. Paul, 1997, Alzheimer disease and associated disorders.

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).

P. Conaghan, V. Kraus, A. Kivitz, 2018, Osteoarthritis and cartilage.

Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis

F. Berenbaum, P. Conaghan, N. Bodick, 2017, Arthritis & rheumatology.

An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials

V. Strand, D. Hunter, F. Berenbaum, 2017 .

An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial.

D. Hunter, J. Bolognese, N. Bodick, 2015, The Journal of bone and joint surgery. American volume.

Efficacy and Safety of FX201, a Novel Intra-Articular IL-1Ra Gene Therapy for Osteoarthritis Treatment, in a Rat Model

R. Boyce, N. Bodick, Agathe Bédard, 2021, Human gene therapy.

Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative

B. Dube, P. Conaghan, M. Bowes, 2020, Annals of the Rheumatic Diseases.

Xanomeline, A Specific M1 Agonist: Early Clinical Studies

L. Farde, T. Gillespie, N. Cutler, 1994 .

Dose-dependent chondroprotective effects of triamcinolone acetonide on inflamed and injured cartilage using an in vitro model

A. Grodzinsky, E. Frank, Y. Krishnan, 2019, Osteoarthritis and Cartilage.

A more rational approach to new-product development.

Eric Bonabeau, E. Bonabeau, R. W. Armstrong, 2008, Harvard business review.

Microtubular disarray in cortical dendrites and neurobehavioral failure. II. Computer reconstruction of perturbed microtubular arrays.

J. Stevens, D. Purpura, N. Bodick, 1982, Brain research.

Growing optic nerve fibers follow neighbors during embryogenesis.

C. Levinthal, N. Bodick, C Levinthal, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.

P. Renshaw, L. Wald, J. Hennen, 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

W W Offen, W. Offen, N. Cutler, 1998, Alzheimer disease and associated disorders.

Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

S H Ferris, B. Dubois, R. Mohs, 1997, Alzheimer disease and associated disorders.

A single intra-articular dose of Fx006, an extended-release formulation of triamcinolone acetonide, has a similar effect on cartilage in healthy dogs as the commonly used kenalog-40® suspension

D. Garlick, N. Bodick, C. Spainhour, 2014 .

Serial reconstruction of microtubular arrays within dendrites of the cat retinal ganglion cell: The cytoskeleton of a vertebrate dendrite

J. Stevens, John K. Stevens, N. Bodick, 1983, Brain Research.

Safety and efficacy of FX006 in patients with osteoarthritis of the knee

D. Hunter, J. Bolognese, N. Bodick, 2014 .

Microtubule disarray in cortical dendrites and neurobehavioral failure. I. Golgi and electron microscopic studies.

I. Rapin, D. Purpura, N. Bodick, 1982, Brain research.

FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis

C. Inderjeeth, N. Bodick, C. Willwerth, 2013 .

Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group.

M N Rossor, R J Harvey, S Shimohama, 1997, Alzheimer disease and associated disorders.

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

J Huff, R. Mohs, H. Feldman, 1997, Alzheimer disease and associated disorders.